Investment Rating - The investment rating for the company is "Buy" with expectations of a relative increase of over 15% compared to the market in the next six months [4][15]. Core Insights - The company achieved a revenue of 895 million yuan in the first half of 2025, representing a year-on-year growth of 20.31%. The net profit attributable to shareholders was 188 million yuan, up 4.16% year-on-year [1][2]. - The revenue growth is attributed to an expanded product matrix, new collaborations with Sam's Club, and strong performance on e-commerce platforms like Tmall, JD.com, Douyin, and Pinduoduo [2][3]. - The company launched over 40 new products in the first half of 2025, including children's sunscreen and acne treatment products, enhancing its product offerings [3]. Summary by Sections Financial Performance - In the first half of 2025, the company reported a net profit of 188 million yuan, with a non-recurring net profit of 177 million yuan, indicating a slower growth rate due to declining gross margins and increased sales expenses [2][3]. - The operating cash flow for the first half of 2025 was 133 million yuan, down 5.30% year-on-year, primarily due to increased accounts receivable from Sam's Club [2]. Profitability - The gross margin decreased by 0.63 percentage points to 58.01%, while the net margin fell by 3.25 percentage points to 20.95%, indicating a decline in profitability [3]. - The sales expense ratio increased by 1.52 percentage points to 30.25%, driven by higher promotional and employee compensation costs [3]. Product and Channel Development - The company’s revenue from mosquito repellent, baby care, and essential oil products was 375 million yuan, 405 million yuan, and 92 million yuan respectively, with significant growth in baby care products [3]. - The company is actively expanding its offline channels, having established a new partnership with Sam's Club, which has contributed to rapid growth in non-platform distribution channels [3]. Future Projections - Revenue forecasts for 2025 to 2027 are set at 1.614 billion yuan, 1.942 billion yuan, and 2.343 billion yuan respectively, with expected growth rates of 22.47%, 20.29%, and 20.65% [4][9]. - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 0.84 yuan, 1.00 yuan, and 1.19 yuan respectively, with corresponding price-to-earnings (PE) ratios of 38, 31, and 27 [4][9].

Core Viewpoint - The announcement from Feihe has led to a significant decline in its market value, with a projected revenue drop and net profit decrease for the first half of 2025 compared to the previous year [1][4]. Group 1: Financial Performance - Feihe expects revenue for the first half of 2025 to be approximately 9.1 billion to 9.3 billion yuan, down from 10.1 billion yuan in the same period of 2024, representing a decline of about 8% to 10% [1]. - The projected net profit for the first half of 2025 is estimated to be between 1 billion to 1.2 billion yuan, reflecting a year-on-year decrease of approximately 37% to 47% [1]. - Following the announcement, Feihe's stock price plummeted by 17.02% on the next trading day and an additional 3.17% the following day, resulting in a total market value loss of 10.15 billion HKD, equivalent to approximately 9.28 billion yuan [1]. Group 2: Market Dynamics - The decline in birth rates poses a long-term challenge for the infant formula industry, with Feihe's revenue and profit having previously increased in 2024, but now facing a downturn again in 2025 [1][16]. - Feihe has initiated a substantial fertility subsidy program valued at 1.2 billion yuan to attract potential customers, but this strategy may lead to a price war and does not guarantee revenue growth [2][3]. - Competitors such as Yili and Junlebao have also launched similar subsidy programs, which may dilute the effectiveness of Feihe's efforts to capture market share [3]. Group 3: Inventory and Growth Challenges - Feihe's inventory levels have increased significantly, with stock surpassing 2 billion yuan, and inventory turnover days rising from 80 days in 2021 to 113.7 days in 2024 [6][10]. - The management anticipates completing inventory adjustments by the third quarter of 2025, but the impact of the subsidy program on revenue may be more pronounced in the second half of the year [9][10]. - Analysts from various financial institutions have revised their growth expectations for Feihe, with projections indicating a potential revenue growth of only 0.5% for 2025, down from earlier estimates of 9% [5]. Group 4: Product Strategy and Market Trends - Feihe plans to launch higher-end products in the second half of 2025, aligning with market trends that show growth in the ultra-premium segment of the infant formula market [12][11]. - Data indicates that the ultra-high-end market has seen a year-on-year growth of 13.3% in early 2025, while other segments have experienced declines [12]. - Despite these efforts, the performance of new products remains uncertain, and the overall demand for infant formula is declining due to lower birth rates [13][16]. Group 5: Shareholder Returns - Feihe has announced a minimum share buyback plan of 1 billion yuan and a dividend distribution of no less than 2 billion yuan, aiming to enhance shareholder value [14]. - However, despite these positive initiatives, the negative impact of the company's financial performance has overshadowed these efforts, leading to a significant drop in market capitalization [15].